Navigation Links
Arthroscopic Treatment of Tennis Elbow is Successful

According to new research released today at the annual Meeting of the American Orthopaedic Society for Sports Medicine at the Telus Convention Center,arthroscopic treatment of tennis elbow has shown to be successful at long-term follow-up.

This is the first longitudinal study of arthroscopic treatment of tennis elbow, says lead investigator Champ L. Baker, III, M.D., an orthopaedic resident at the University of Pittsburgh.

The initial success from our original short-term study was maintained long term. I am happy to say that arthroscopic release is a good treatment option for lingering tennis elbow. The patients were enrolled through the Hughston Clinic in Columbus, Ga., where Dr. Bakers father and the senior study investigator, Champ L. Baker, Jr., M.D., practices orthopaedic sports medicine surgery.

Tennis elbow, a potentially debilitating condition, is common and can be successfully managed without surgery in almost 90% of cases. When it cannot be controlled by nonoperative measures, including rest, the arthroscopic technique used in this study is one of the many different surgical options that have good outcomes.

Investigators studied the long-term (130 month) pain and functional scores of 30 patients who underwent arthroscopic release for tennis elbow. The short-term results from this patient group were published in The Journal of Shoulder and Elbow Surgery in 2000 (9:475-82).

The researchers found that arthroscopic treatment provided very good results in terms of long-term pain relief and functional restoration. There were no repeat surgeries or injections. Satisfaction rates were also high, with 93% of the patients stating that they would have the surgery again if needed.

Athletes are not the only population vulnerable to tennis elbow. People in their 40s and 50s who do repetitive activities are often afflicted. Such activities can range from repetitively lifting boxes to repeti
'"/>




Page: 1 2

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
...t body issued a warning today that thousands of pe...ethal doses of radiation.// The warning issued b... (RPII) came after a house in Kerry was discovered...ceptable level of the deadly radioactive and cance...
...rning was issued by Britain's prime minister to th...products that were not-so- healthy to children or ...l ads that target minors. In a broad address on i...rned that in case of the voluntary regulations fai...
... bench of Allahabad High Court today stayed operat...ing 65 per cent seats in unaided private medical//...er government quota. A division bench comprising J...jeev Sharma granted the interim stay on the GO on ...
...ho are at a high risk for developing type 2 diabet...o take up weight training, according to researcher...researcher Michael Goran, PhD, professor of preven...cine of USC and colleagues were able to prove that...
Other Medicine News:Health News:Irish Households Exposed To Lethal Radiation 2Health News:Weight Training Can Ward Off Type 2 Diabetes In teenagers 2
(Date:10/8/2008)...nce Will Reduce Animal Use in Cosmetics and Chemic...-- MatTek Corp. today announced,that results of a ...y,"catch-up" validation study on MatTek,s EpiDerm ...sults demonstrated the required sensitivity and,sp...d alternative to animal,testing for determining hu...
(Date:10/8/2008)... Heart Institute Pioneers Research That May Offer ... 8 /- Nationally, over 3,000 people a...e on life. Sadly, only half,of those will receive ...Heart Institute (AHI) is paving the way for how to...To view the Multimedia News Release, go to:, http:...
(Date:10/8/2008)...ll University Food Scientists Expand Testing Using...ty Assay, PORTLAND, Maine, Oct. 8 /-...y with the release of results from a new study,sho...ommonly consumed,fruits like apples, bananas, red ...the Cellular Antioxidant Activity (CAA) assay. New...
(Date:10/8/2008)...indings Confirm Potency of Poly-ICR as Vaccine Adj...- Nventa Biopharmaceuticals,Corporation (TSX: NVN)...udies using its proprietary Toll-like Receptor 3 a...orld Vaccine Congress 2008 in Lyon, France.,Study ...ne adjuvant,targeting the Toll-like Receptor 3 (TL...
Breaking Medicine Technology:MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 2Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 3Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 4Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress 5A new more effective tuberculosis screening test for HIV victims 13531 1A new more effective tuberculosis screening test for HIV victims 13531 2A new more effective tuberculosis screening test for HIV victims 13531 3HealthMedia Fourth Quarter 2007 Produces Highest Revenue in Company History 13527 1HealthMedia Fourth Quarter 2007 Produces Highest Revenue in Company History 13527 2Governor Rendell Proclaims Older Pennsylvanians Nutrition Awareness Week 13522 1Governor Rendell Proclaims Older Pennsylvanians Nutrition Awareness Week 13522 2Governor Rendell Proclaims Older Pennsylvanians Nutrition Awareness Week 13522 3Rusty worms in the brain 2411 1Rusty worms in the brain 2411 2
...AND OAKS, Calif.--(BUSINESS WIRE)--Apr 16, 2007 - ...om a randomized,double-blind, placebo-controlled ...f Aranesp(R) (darbepoetin alfa) for the,treatment ...ving,chemotherapy or radiotherapy ("the 103 study"...MEA in these patients. These,results were presente...
... Antagonist Demonstrates Clinical Activity, a Nove...ith other HCV Inhibitors-, NEW HAVEN, Conn., April...maceuticals, Inc. today announced the presentation...y of one of,Achillion,s NS4A antagonists, ACH-806,...ction at the 42nd Annual Meeting of the,European A...
Other Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 2Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 4
This unique blanket is designed to be used for many surgical procedures, including but not limited to: laminectomies, spinal procedures, abdominal procedures, and transplants.
The chest access blanket is designed specifically for the thoracic surgery patient.
The cardiac access blanket helps maintain normothermia and allows unrestricted access to the patient.
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces
Medicine Products: